363 related articles for article (PubMed ID: 8260357)
21. Effects of glutathione depletion on the cytotoxicity of agents toward a human colonic tumour cell line.
Jordan J; d'Arcy Doherty M; Cohen GM
Br J Cancer; 1987 Jun; 55(6):627-31. PubMed ID: 3620304
[TBL] [Abstract][Full Text] [Related]
22. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
23. Chemosensitization by buthionine sulfoximine in vivo.
Tsutsui K; Komuro C; Ono K; Nishidai T; Shibamoto Y; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1183-6. PubMed ID: 2427490
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.
Bailey HH; Ripple G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Mahvi D; Schink J; Pomplun M; Mulcahy RT; Wilding G
J Natl Cancer Inst; 1997 Dec; 89(23):1789-96. PubMed ID: 9392620
[TBL] [Abstract][Full Text] [Related]
25. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen G; Waxman DJ
Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907
[TBL] [Abstract][Full Text] [Related]
26. The effect of glutathione (GSH) depletion in vivo by buthionine sulfoximine (BSO) on the radiosensitization of SR 2508.
Kramer RA; Soble M; Howes AE; Montoya VP
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1325-9. PubMed ID: 2523885
[TBL] [Abstract][Full Text] [Related]
27. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
Dethlefsen LA; Lehman CM; Biaglow JE; Peck VM
Radiat Res; 1988 May; 114(2):215-24. PubMed ID: 3375425
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine.
Ono K; Shrieve DC
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1175-8. PubMed ID: 3091546
[TBL] [Abstract][Full Text] [Related]
29. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo.
Révész L; Edgren MR; Wainson AA
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):403-6. PubMed ID: 8195041
[TBL] [Abstract][Full Text] [Related]
30. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
Bier H
Laryngorhinootologie; 1990 Jan; 69(1):16-20. PubMed ID: 2310456
[TBL] [Abstract][Full Text] [Related]
31. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
Prezioso JA; FitzGerald GB; Wick MM
J Invest Dermatol; 1992 Sep; 99(3):289-93. PubMed ID: 1512464
[TBL] [Abstract][Full Text] [Related]
32. Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice.
Soble MJ; Dorr RT
Res Commun Chem Pathol Pharmacol; 1987 Feb; 55(2):161-80. PubMed ID: 3823607
[TBL] [Abstract][Full Text] [Related]
33. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
[TBL] [Abstract][Full Text] [Related]
34. Tissue-specific changes in glutathione and cysteine after buthionine sulfoximine treatment of rats and the potential for artifacts in thiol levels resulting from tissue preparation.
Standeven AM; Wetterhahn KE
Toxicol Appl Pharmacol; 1991 Feb; 107(2):269-84. PubMed ID: 1994510
[TBL] [Abstract][Full Text] [Related]
35. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508.
Yu NY; Brown JM
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1265-9. PubMed ID: 6236185
[TBL] [Abstract][Full Text] [Related]
36. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.
Villablanca JG; Volchenboum SL; Cho H; Kang MH; Cohn SL; Anderson CP; Marachelian A; Groshen S; Tsao-Wei D; Matthay KK; Maris JM; Hasenauer CE; Czarnecki S; Lai H; Goodarzian F; Shimada H; Reynolds CP
Pediatr Blood Cancer; 2016 Aug; 63(8):1349-56. PubMed ID: 27092812
[TBL] [Abstract][Full Text] [Related]
37. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
[TBL] [Abstract][Full Text] [Related]
38. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
[TBL] [Abstract][Full Text] [Related]
39. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.
O'Dwyer PJ; Hamilton TC; Young RC; LaCreta FP; Carp N; Tew KD; Padavic K; Comis RL; Ozols RF
J Natl Cancer Inst; 1992 Feb; 84(4):264-7. PubMed ID: 1734088
[No Abstract] [Full Text] [Related]
40. Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro.
Du DL; Volpe DA; Grieshaber CK; Murphy MJ
Cancer Res; 1990 Jul; 50(13):4038-43. PubMed ID: 2354454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
